Piramal Pharma Limited

Piramal Pharma Limited (PPLPHARMA) is a mid-cap Healthcare company valued at ₹26,325 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Piramal Pharma Limited last traded at ₹197.47, modestly up 1.56% on the day.

Recent developments

On 2026-09-15, the USFDA issued 7 observations at the UK facility, which could impact operations. On 2026-07-31, the company reported a surge in Q1 EBITDA to ₹285 crore and reaffirmed its FY27 capital expenditure guidance. On 2026-07-30, the stock rose after reporting improved results and guidance for potential profitability in FY27.

Financial performance

The company's business has deteriorated, with annual net profit showing a loss of ₹326 crore. Revenue grew at a 6.2% CAGR over five years but has struggled to translate into profitability, as the latest quarter saw a loss narrowing from ₹82 crore to ₹69 crore, though the company remains unprofitable.

Valuation multiples

A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 3.46 times book value.

Things to watch

The company reported a net loss of ₹326 crore in the latest financial year, with a net profit margin of -3.7%. The stock is 14.6% below its 52-week high, and foreign institutional holdings fell by 17.66 percentage points in the quarter.

Where it stands

Piramal Pharma Limited remains unprofitable, with a net loss of ₹326 crore in the latest financial year. The latest quarter saw a narrowing loss, but the company continues to operate at a loss. The stock is 14.6% below its 52-week high, and foreign institutional holdings have declined significantly.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.